Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GIGA-564 |
| Synonyms | |
| Therapy Description |
GIGA-564 is a monoclonal antibody targeting CTLA-4, which potentially induces FcR signaling and anti-tumor activity (Cancer Immunol Res (2022) 10 (12_Supplement): A32). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GIGA-564 | GIGA564|GIGA 564 | CTLA4 Antibody 33 | GIGA-564 is a monoclonal antibody targeting CTLA-4, which potentially induces FcR signaling and anti-tumor activity (Cancer Immunol Res (2022) 10 (12_Supplement): A32). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06258304 | Phase I | GIGA-564 | A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | Recruiting | USA | 0 |